

Daedalus Fund **Momentum** in Action

The Daedalus Fund has already helped many Weill Cornell Medicine physician-scientists move discoveries forward on the critical path from the lab bench to the marketplace. Here are just a few examples of this momentum in action:

“Our research aims to develop a new, non-opioid treatment for neuropathic pain, a debilitating condition that affects up to 30 million people in this country, and a larger number worldwide.

“We are focused on developing treatment modalities that target the HCN1 channel, a protein that is embedded in the cell membrane and is implicated in neuropathic pain associated with a variety of pathologic conditions. With Daedalus funding, we were able to synthesize a number of new molecules with the desired targeting properties – with the help of Dr. Anthony Sauve in the Department of Pharmacology – that inhibited HCN1.

“We have identified a lead compound that appears to have selectivity for HCN1 channels, and we will continue to test improved versions of the compound to further establish its efficacy as a pain reliever.

“At this stage, we are ready to partner with a biopharma company to develop novel, first-in-class medications that will offer meaningful relief to patients with neuropathic pain.

“As envisioned by Larry Schlossman, managing director of BioPharma Alliances and Research Collaborations at Weill Cornell Medicine, the Daedalus Fund has been fundamental in our ability to move this project forward.”

Peter Goldstein, MD
Professor of Anesthesiology
Weill Cornell Medicine



We are ready to partner with a biopharma company to **develop novel, first-in-class medications that will offer meaningful relief** to patients with neuropathic pain.